Navigation Links
Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
Date:10/31/2007

SYMBOL - BCL.P

VANCOUVER, Oct. 31 /PRNewswire-FirstCall/ - Beanstalk Capital Ltd. ( the "Company") is pleased to announce that further to the Company's press release dated October 16, 2007, in which the Company and iCo Therapeutics Inc. ("iCo") announced that they had entered into an arm's length arrangement agreement dated October 15, 2007 (the "Arrangement Agreement"), the Company and iCo would now like to announce that they have entered into an amended and restated Arrangement Agreement dated October 25, 2007. Under the amended and restated Arrangement Agreement the brokered equity financing for the proposed transaction will now be conducted through iCo, rather than the Company. Canaccord Capital Corporation will act as the lead agent for the private placement and Haywood Securities Inc. will participate as a syndicate member. The brokered financing will consist of the sale of 1,840,000 subscription receipts of iCo at $0.98 per subscription receipt to raise gross proceeds of $1,803,200. Canaccord will have the option to increase the size of the offering by selling up to an additional 1,020,000 subscription receipts for additional gross proceeds of $999,600. The proceeds from the sale of the subscription receipts will be held in escrow by a third party pending closing of the qualifying transaction ("QT"). As a result of now raising funds in iCo and completing the QT under a plan of arrangement, the shares issued upon exercise of the subscription receipts subscribed for in this financing will be free trading upon closing of the QT.

Significant Conditions to Closing of QT

Completion of the transaction is subject to a number of conditions including, without limitation, approval by iCo's shareholders, approval of the Supreme Court of British Columbia and the TSX Venture Exchange, and completion by iCo of a private placement of subscription receipts having a minimum aggregate subscription price of $1,803,200. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management

information circular or filing statement to be prepared in connection

with the transaction, any information released or received with respect

to the transaction may not be accurate or complete and should not be

relied upon. Trading in the securities of a capital pool company should

be considered highly speculative.

The TSX Venture Exchange has in no way passed upon the merits of the

proposed transaction and has neither approved nor disapproved the

contents of this press release.

CONTACT: Rod Shier, Chief Financial Officer, Beanstalk Capital Ltd., Telephone: (604) 682-2992 Ext. 222; John Meekison, Chief Financial Officer, iCo Therapeutics Inc., Telephone: (604) 602-9414 Ext. 224


'/>"/>
SOURCE Beanstalk Capital Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Breaking down Wisconsins angel capital numbers
2. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
3. Visions: Broderick says Wisconsin should be in top third in venture capital
4. In pursuit of capital, be sure to track your private offering
5. Wisconsin building toward the major leagues of venture capital
6. Research explains why women lack equal access to angel capital
7. When raising capital, why use a Private Placement Memorandum?
8. Capital-raising term sheets for angels and venture capitalists
9. Early Stage, Step 9: Raising capital in the securities landscape
10. Translating the language of capital-raising
11. Visions: Carbone bullish on Wisconsin venture capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
(Date:3/23/2017)... ... 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), a ... “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will lead ... Floyd’s career has spanned 30 years in the chemicals and equipment industries. Sig ...
(Date:3/22/2017)... Calif. , March 22, 2017  UBM ... proud to announce their extended partnership and the ... be headlined by the 21 st Annual ... Boston, taking place May 3-4, 2017. ... Medical Technology Association (ADVAMED) President and CEO, ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):